Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levoketoconazole - Strongbridge Biopharma

Next Previous
Drug Profile

Levoketoconazole - Strongbridge Biopharma

Alternative Names: (2S,4R)-ketoconazole; 2S-4R-ketoconazole; COR-003; DIO 902; Levdexketoconazole - StrongBridge Biopharma; NormoCort; RECORLEV

Latest Information Update: 09 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cortendo
  • Developer Strongbridge Biopharma
  • Class Antihyperglycaemics; Chlorobenzenes; Dioxolanes; Imidazoles; Piperazines; Small molecules
  • Mechanism of Action 14-alpha demethylase inhibitors; Mixed function oxygenase inhibitors; Steroid 11-beta-hydroxylase inhibitors; Steroid 17-alpha-hydroxylase inhibitors; Steroid 21 hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cushing syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cushing syndrome
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 09 Jun 2024 Levoketoconazol has boxed warning of hepatotoxicity and QT prolongation
  • 30 Jan 2023 The US FDA grants Orphan Drug Exclusivity (ODE) for levoketoconazole for Cushing’s syndrome
  • 01 Nov 2022 Efficacy and safety data from the phase III SONICS trial in Cushing syndrome released by Xeris Biopharma Holdings

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top